Bicara Therapeutics said a leadership transition is aimed at accelerating growth as its pivotal Phase 2/3 FORTIFI-HN01 trial advances. The Q2 update also flagge

Bicara Therapeutics said a leadership transition is aimed at accelerating growth as its pivotal Phase 2/3 FORTIFI-HN01 trial advances. The Q2 update also flagged near-term milestones and new board appointments for Jeremy Bender and Christy Oliger.